Accretion Pharmaceuticals Ltd vs Ambalal Sarabhai Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 08, 2026

Key Highlights

The Latest Trading Price of Accretion Pharmaceuticals Ltd is ₹ 117.75 as of 08 May 15:40 . The P/E Ratio of Accretion Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Ambalal Sarabhai Enterprises Ltd changed from 4.6 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 64.14% over 5 years The Market Cap of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Ambalal Sarabhai Enterprises Ltd changed from ₹ 135.26 crore on March 2021 to ₹ 268.6 crore on March 2025 . This represents a CAGR of 14.71% over 5 years The revenue of Accretion Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 54.76 crore as compare to the Sep '25 revenue of ₹ 46.07 crore. This represent the growth of 18.86% The ebitda of Accretion Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Ambalal Sarabhai Enterprises Ltd for the Dec '25 is ₹ 6.02 crore as compare to the Sep '25 ebitda of ₹ 1.98 crore. This represent the growth of 204.04% The net profit of Accretion Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Ambalal Sarabhai Enterprises Ltd changed from ₹ 0.35 crore to ₹ 3.64 crore over 7 quarters. This represents a CAGR of 281.21% The Dividend Payout of Accretion Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ambalal Sarabhai Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals was incorporated in year 2012, the Promoters Mr. Harshad Nanubhai Rathod, Mr. Vivek Ashok Kumar Patel, Mr. Mayur Popatlal Sojitra and Mr. Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, to provide health care products.
Thus, the foundation of 'Accretion Pharmaceuticals' was laid down, which was started as a Partnership Firm in the name of 'M/s Accretion Pharmaceuticals', pursuant to a deed of partnership dated December 18, 2012. The manufacturing facility which is currently located at Ahmedabad, in Sanand District of Gujarat, commenced its manufacturing operations in 2014.
Thereafter, the Partnership Firm was converted into a Limited Company in the name of 'Accretion Pharmaceuticals Limited' and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Limited, incorporated on June 27, 1977, houses a range of companies across multi-dimensional businesses.
It is one of the oldest pharmaceutical health care companies in India, and through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments.
Pharmaceuticals segment is engaged in manufacture of drugs and formulations.
Electronics segment is engaged in manufacture of electronics instruments and services. In 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company.

FAQs for the comparison of Accretion Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd

Which company has a larger market capitalization, Accretion Pharmaceuticals Ltd or Ambalal Sarabhai Enterprises Ltd?

Market cap of Accretion Pharmaceuticals Ltd is 125 Cr while Market cap of Ambalal Sarabhai Enterprises Ltd is 243 Cr

What are the key factors driving the stock performance of Accretion Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd?

The stock performance of Accretion Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd?

As of May 8, 2026, the Accretion Pharmaceuticals Ltd stock price is INR ₹112.5. On the other hand, Ambalal Sarabhai Enterprises Ltd stock price is INR ₹31.79.

How do dividend payouts of Accretion Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd compare?

To compare the dividend payouts of Accretion Pharmaceuticals Ltd and Ambalal Sarabhai Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.